Biotech Archives - Page 676 of 795

2 minute read

Y-mAbs Highlights Presentation Of Pivotal Data For Omburtamab

October 3, 9:04 AM

Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic

YMAB

4 minute read

Google Now Shuts Down Translate App In China, Moderna-China COVID-19 Sales Talk Collapse, Disney-Dish Temporary Accord Ends Weekend Blackout: Top Stories Monday, Oct. 03

By Vandana Singh

October 3, 9:02 AM

Wall Street Journal

AMZN

1 minute read

Altamira Therapeutics Announces Its NASAR Clinical Trial With Bentrio Has Resu,ed Enrollment

By Benzinga Newsdesk

October 3, 8:49 AM

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its "NASAR" clinical trial with its BentrioTM nasal

CYTO

2 minute read

New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care

By Benzinga Newsdesk

October 3, 8:46 AM

Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor

DXR

1 minute read

Soleno Therapeutics Announces Initiation Of Randomized Withdrawal Study Of DCCR For Treatment Of Prader-Willi Syndrome

By Benzinga Newsdesk

October 3, 8:09 AM

Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a

SLNO

1 minute read

NEXGEL Highlights Publication Of Study Evaluating SilverSeal In SAGE Journals’ Scars, Burns And Healing

By Benzinga Newsdesk

October 3, 7:35 AM

NEXGEL, Inc. (NASDAQ:NXGL, NXGLW)))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced

NXGL

1 minute read

OpGen Announces Successful Completion Of Clinical Trial Enrollment For Unyvero Urinary Tract Infection Panel

By Benzinga Newsdesk

October 3, 7:31 AM

Prospective multicenter trial for the Unyvero UTI Panel has successfully completed enrollment of patient samples Urine samples have been collected from over 1,800 patients at 4 U.S. clinical trial sites Clinical

OPGN

1 minute read

Why Are LogicBio Therapeutics Shares Skyrocketing Today?

By Vandana Singh

October 3, 7:21 AM

AstraZeneca Plc’s (NASDAQ:AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ:LOGC) for $2.07 per share. Both boards have unanimously approved…

AZN

1 minute read

RedHill’s Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5

By Benzinga Newsdesk

October 3, 7:13 AM

Novel, oral, host-targeted, broad-acting antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib, demonstrated in vitro inhibition of the COVID-19-causing SARS-Cov-2 Omicron BA.5 sub-variant in testing

RDHL

3 minute read

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration Of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma Presented At AAO 2022

By Benzinga Newsdesk

October 3, 7:11 AM

Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Phase 2

AURA